Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ADMA Biologics Inc (NASDAQ: ADMA).

Full DD Report for ADMA

You must become a subscriber to view this report.


Recent News from (NASDAQ: ADMA)

FDA accepts ADMA Bio's refiled marketing application for RI-002, action date April 2, 2019
The FDA has accepted for review ADMA Biologics' (NASDAQ: ADMA ) resubmitted BLA seeking approval for lead candidate RI-002 for the treatment of patients with primary immune deficiency disease (PIDD). It received a CRL in July 2016 in response to its original filing. More news on: ADMA Bi...
Source: SeekingAlpha
Date: October, 17 2018 07:52
ADMA Biologics Receives PDUFA Date for RI-002
Resubmission of Biologics License Application (“BLA”) Reinforces the Company’s Commitment to Commercialize Novel Therapies for Immune Compromised Patients to Address Unmet Medical Needs RAMSEY, N.J. and BOCA RATON, Fla., Oct. 17, 2018 (GLOBE NEWSWIRE) -- ADMA Bio...
Source: GlobeNewswire
Date: October, 17 2018 07:08
ADMA Biologics Provides Regulatory Update for BIVIGAM®
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 11, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops s...
Source: GlobeNewswire
Date: October, 11 2018 08:48
ADMA BioCenters receives FDA approval for third plasma collection center
ADMA Biologics (NASDAQ: ADMA ) announces that the Company’s wholly-owned subsidiary, ADMA BioCenters, has received FDA approval for its third plasma collection center, located at 166 Ernest W Barrett Parkway, NW, Marietta, Georgia. More news on: ADMA Biologics Inc, Dominion Energy...
Source: SeekingAlpha
Date: October, 03 2018 07:29
ADMA BioCenters Receives FDA Approval for Third Plasma Collection Center
RAMSEY, N.J. and MARIETTA, Ga., Oct. 03, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for...
Source: GlobeNewswire
Date: October, 03 2018 07:08
ADMA Biologics resubmits BLA for RI-002
ADMA Biologics (NASDAQ: ADMA ) has responded to the July 2016 Complete Response Letter (“CRL”) and resubmitted its Biologics License Application (“BLA”) for RI-002 to the FDA on September 28, 2018. More news on: ADMA Biologics Inc, Healthcare stocks news, Stoc...
Source: SeekingAlpha
Date: October, 01 2018 09:04
ADMA Biologics Resubmits Biologics License Application for RI-002
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics ...
Source: GlobeNewswire
Date: October, 01 2018 07:08
ADMA Biologics: Finish Line Ahead?
"Revolution is a spectator sport. The majority will sit in the stands and watch the factions fight. At the end they will choose sides with the team that is winning." - George Lincoln Rockwell Today, we look at a "Busted IPO" that has caused its shareholders angina over the past year due to...
Source: SeekingAlpha
Date: September, 06 2018 11:59
ADMA Biologics Reports FDA Compliance Status for its Manufacturing Facility has Improved
FDA Inspection Database Confirms VAI Status of Boca Raton, FL Facility RI-002’s Biologics License Application (“BLA”) Resubmission Targeted for Third Quarter 2018 RAMSEY, N.J. and BOCA RATON, Fla., Sept. 05, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc...
Source: GlobeNewswire
Date: September, 05 2018 07:08
ADMA Biologics: Buy Or Sell Before Bivigam PDUFA?
ADMA Biologics (ADMA) shares are already up 10% in less than a week since the trade was mentioned to subscribers of the premium Marketplace service. They have more upside ahead. (Source: Finviz) Investment thesis Catalyst: PDUFA for BIVIGAM (iv immunoglobulin) in treating primary humoral...
Source: SeekingAlpha
Date: August, 30 2018 23:34

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-086.576.306.59856.24184,189
2018-05-175.145.425.55695.1241466,540
2017-06-203.143.00013.142.9747,256
2017-06-193.053.0343.053.000133,765
2017-06-163.1693.0453.16992.9691,553

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1034,71554,07864.1943Short
2018-12-077,29022,67332.1528Cover
2018-12-0652,42882,79863.3204Short
2018-12-0434,97393,01337.6001Short
2018-12-0325,51761,91441.2136Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ADMA.


About ADMA Biologics Inc (NASDAQ: ADMA)

Logo for ADMA Biologics Inc (NASDAQ: ADMA)

ADMA Biologics is a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma based biologics for the treatment and prevention of certain infectious diseases. Our targeted patient populations include immune compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune suppressed for medical reasons. Our product candidates are intended to be used by physician specialists focused on caring for immune compromised patients with infectious diseases. ADMA also operates ADMA BioCenters, an FDA licensed, GHA certified source plasma collection facility which provides a portion of blood plasma for the manufacture of the our lead product candidate RI .

 

Contact Information

 

 

Current Management

  • Adam S. Grossman / President, CEO, Founder
    • Mr. Grossman has been a director of ADMA since , has served as ADMA s President and Chief Executive Officer since October and as ADMA s President and Chief Operating Officer between and October . Mr. Grossman has over years experience in the blood and plasma industry. Prior to founding ADMA, Mr. Grossman was the Executive Vice President of National Hospital Specialties and GenesisBPS, a position he held between and . He has experience in launching new products, building and managing national and international sales forces, managing clinical trials, and completing numerous business development transactions. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins, and at the American Red Cross, where he launched new products with the Biomedical Services division. Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University. Mr. Grossman is the son of Dr. Jerrold B. Grossman, our Vice Chairman. Mr. Grossman was chosen to serve on the Board of Directors because, as ADMA s Chief Executive Officer, he is able to provide the Board with critical insight into our daytoday operations.
  • Brian Lenz / CFO
  • Steven A. Elms / Chairman
    • Mr. Elms serves as a Managing Partner at Aisling Capital, which he joined in . Previously, he was a Principal in the Life Sciences Investment Banking Group of Hambrecht amp Quist. During his five years at Hambrecht amp Quist, Mr. Elms was involved in over financing and merger and acquisition transactions, helping clients raise in excess of . billion in capital. Prior to joining Hambrecht amp Quist, Mr. Elms traded mortgagebacked securities at Donaldson, Lufkin amp Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories and two years as a consultant for The Wilkerson Group. Mr. Elms received a B.A. in Human Biology from Stanford University and an M.B.A. from Kellogg Graduate School of Management at Northwestern University. Mr. Elms serves on the boards of Ambit Biosciences Corporation, Pernix Therapeutics Holdings, Inc. and a number of other private companies. Mr. Elms was chosen to serve on the Board of Directors because of his valuable experience in the investment and investment banking industry, particularly with respect to strategic and financing transactions.
  • Adam S. Grossman / Director
    • Mr. Grossman has been a director of ADMA since , has served as ADMA s President and Chief Executive Officer since October and as ADMA s President and Chief Operating Officer between and October . Mr. Grossman has over years experience in the blood and plasma industry. Prior to founding ADMA, Mr. Grossman was the Executive Vice President of National Hospital Specialties and GenesisBPS, a position he held between and . He has experience in launching new products, building and managing national and international sales forces, managing clinical trials, and completing numerous business development transactions. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins, and at the American Red Cross, where he launched new products with the Biomedical Services division. Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University. Mr. Grossman is the son of Dr. Jerrold B. Grossman, our Vice Chairman. Mr. Grossman was chosen to serve on the Board of Directors because, as ADMA s Chief Executive Officer, he is able to provide the Board with critical insight into our daytoday operations.

Current Share Structure

  • Market Cap: $238,368,703 - 05/14/2018
  • Authorized: 75,000,000 - 12/31/2012
  • Issue and Outstanding: 45,317,244 - 03/09/2018

 


Recent Filings from (NASDAQ: ADMA)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 03 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: April, 27 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018

 

 


Daily Technical Chart for (NASDAQ: ADMA)

Daily Technical Chart for (NASDAQ: ADMA)


Stay tuned for daily updates and more on (NASDAQ: ADMA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ADMA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ADMA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ADMA and does not buy, sell, or trade any shares of ADMA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/